Niraparib

證據等級: L5

預測適應症: 10 個

Niraparib: From Ovarian Cancer to Epiglottis Neoplasm

One-Sentence Summary

Niraparib is a PARP inhibitor established as maintenance therapy for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (per trial/literature records in this evidence pack; structured regulatory fields for original indication and MOA are not populated). The TxGNN model's top-ranked prediction for this drug is Epiglottis Neoplasm, but this candidate currently has zero clinical trials and zero publications supporting it — the prediction rests entirely on model score.

Quick Overview

Item	Content
Original Indication	Ovarian cancer (maintenance treatment of recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer) — derived from trial/literature text; structured field is a data gap
Predicted New Indication	Epiglottis Neoplasm
TxGNN Prediction Score	99.99%
Evidence Level	L5
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the structured drug record (original_moa: [Data Gap]). Based on information found elsewhere in this evidence pack, niraparib is a PARP (poly ADP-ribose polymerase) inhibitor that exploits synthetic lethality in tumors with homologous recombination deficiency (HRD), including BRCA1/2 mutations — it is used clinically as maintenance therapy in platinum-sensitive, BRCA-mutated or HRD-positive ovarian cancer.

Epiglottis neoplasm falls under head and neck squamous cell carcinoma, a tumor type with a very low prevalence of HRD/BRCA mutations compared to high-grade serous ovarian cancer. There is no established biological rationale connecting niraparib's synthetic-lethality mechanism to this tumor site.

Consequently, this prediction should be treated as a pure model-score signal rather than a mechanistically or clinically supported hypothesis. The high TxGNN score most likely reflects embedding similarity in the knowledge graph rather than genuine biological plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Cytotoxicity

Niraparib is an antineoplastic (targeted anticancer) agent, so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (PARP inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial or literature evidence for niraparib in epiglottis neoplasm, and the mechanistic link is theoretical at best given the low HRD/BRCA prevalence in head and neck cancers — this is an L5, model-only prediction. Notably, a lower-ranked candidate in this evidence pack, "cystic neoplasm" (largely reflecting high-grade serous ovarian/endometrial serous carcinoma), has substantially stronger support (3 trials, 9 publications, L2/S2) and may warrant separate evaluation.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) — currently a Blocking data gap preventing entry into S1 safety review
Confirmed mechanism-of-action documentation from DrugBank
Preclinical or mechanistic data on PARP inhibitor activity in laryngeal/hypopharyngeal tumors, or HRD/BRCA mutation prevalence data specific to epiglottis neoplasm
If pursuing repurposing further, prioritize the higher-evidence "cystic neoplasm" (HGSOC/endometrial serous carcinoma) candidate instead
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.